MX2022011817A - Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. - Google Patents

Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.

Info

Publication number
MX2022011817A
MX2022011817A MX2022011817A MX2022011817A MX2022011817A MX 2022011817 A MX2022011817 A MX 2022011817A MX 2022011817 A MX2022011817 A MX 2022011817A MX 2022011817 A MX2022011817 A MX 2022011817A MX 2022011817 A MX2022011817 A MX 2022011817A
Authority
MX
Mexico
Prior art keywords
n3pglu
amyloid beta
beta peptide
peptide antibodies
antibodies
Prior art date
Application number
MX2022011817A
Other languages
English (en)
Inventor
Jirong Lu
Ying Tang
Ronald Bradley Demattos
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2022011817A publication Critical patent/MX2022011817A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos anti-N3pGlu Aß humana, composiciones que comprenden tales anticuerpos anti-N3pGlu Aß, y métodos de uso tales anticuerpos anti-N3pGlu Aß para el tratamiento de una enfermedad caracterizada por la deposición de Aß que incluye la enfermedad de Alzheimer clínica o preclínica, síndrome de Down, y angiopatía amiloide cerebral clínica o preclínica.
MX2022011817A 2017-04-20 2019-10-17 Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. MX2022011817A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20

Publications (1)

Publication Number Publication Date
MX2022011817A true MX2022011817A (es) 2022-10-10

Family

ID=62111232

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012445A MX2019012445A (es) 2017-04-20 2018-04-16 Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.
MX2022011817A MX2022011817A (es) 2017-04-20 2019-10-17 Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019012445A MX2019012445A (es) 2017-04-20 2018-04-16 Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.

Country Status (28)

Country Link
US (3) US10647759B2 (es)
EP (1) EP3612559A1 (es)
JP (3) JP6900500B2 (es)
KR (2) KR102352670B1 (es)
CN (2) CN110582511B (es)
AR (1) AR111208A1 (es)
AU (2) AU2018255221B2 (es)
BR (1) BR112019018810A2 (es)
CA (1) CA3058482C (es)
CL (1) CL2019002922A1 (es)
CO (1) CO2019011349A2 (es)
CR (1) CR20190445A (es)
DO (1) DOP2019000241A (es)
EA (1) EA201992163A1 (es)
EC (1) ECSP19075146A (es)
IL (1) IL269003A (es)
JO (1) JOP20190247A1 (es)
MA (1) MA50144A (es)
MX (2) MX2019012445A (es)
NZ (1) NZ758066A (es)
PE (1) PE20200011A1 (es)
PH (1) PH12019502361A1 (es)
SA (1) SA519410311B1 (es)
SG (1) SG11201909022PA (es)
TW (2) TWI705975B (es)
UA (1) UA126806C2 (es)
WO (1) WO2018194951A1 (es)
ZA (1) ZA202007868B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
CR20210492A (es) 2019-03-26 2021-11-19 Janssen Pharmaceutica Nv ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS
WO2021151011A2 (en) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof
PE20231507A1 (es) 2020-10-02 2023-09-26 Lilly Co Eli Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped
TW202243690A (zh) 2021-01-11 2022-11-16 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
JP7306745B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7306746B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
WO2023070064A1 (en) * 2021-10-22 2023-04-27 Eli Lilly And Company O-glcnacase (oga) inhibitor combination therapy
JP2023067832A (ja) * 2021-10-29 2023-05-16 イーライ リリー アンド カンパニー インターロイキン－３４を標的とする化合物及び方法
TW202334210A (zh) 2021-10-29 2023-09-01 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
WO2023076970A1 (en) * 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
WO2023076971A1 (en) 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101670105B (zh) * 2000-02-24 2014-08-06 华盛顿大学 螯合淀粉样蛋白β肽的人源化抗体
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
MY148086A (en) * 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
MX2010013647A (es) 2008-06-12 2011-04-05 Affiris Ag Compuestos para tratar sintomas asociados con la enfermedad de parkinson.
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
PL3339323T3 (pl) * 2010-08-12 2020-05-18 Eli Lilly And Company Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
KR102405104B1 (ko) * 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Also Published As

Publication number Publication date
JP2020510081A (ja) 2020-04-02
CN117024583A (zh) 2023-11-10
DOP2019000241A (es) 2019-10-15
CL2019002922A1 (es) 2020-03-13
KR102567295B1 (ko) 2023-08-16
JP7227312B2 (ja) 2023-02-21
JP2023058623A (ja) 2023-04-25
JOP20190247A1 (ar) 2019-10-20
EA201992163A1 (ru) 2020-03-02
US20210371509A1 (en) 2021-12-02
TWI705975B (zh) 2020-10-01
CA3058482C (en) 2023-05-09
CA3058482A1 (en) 2018-10-25
CN110582511B (zh) 2023-08-08
CR20190445A (es) 2019-11-06
NZ758066A (en) 2022-10-28
PH12019502361A1 (en) 2020-07-13
ZA202007868B (en) 2023-06-28
SA519410311B1 (ar) 2022-03-20
UA126806C2 (uk) 2023-02-08
EP3612559A1 (en) 2020-02-26
AR111208A1 (es) 2019-06-12
SG11201909022PA (en) 2019-11-28
US20200262902A1 (en) 2020-08-20
US10647759B2 (en) 2020-05-12
WO2018194951A1 (en) 2018-10-25
JP2021151253A (ja) 2021-09-30
TW201902924A (zh) 2019-01-16
BR112019018810A2 (pt) 2020-05-05
IL269003A (en) 2019-10-31
CO2019011349A2 (es) 2019-10-31
US20180305444A1 (en) 2018-10-25
AU2018255221B2 (en) 2021-07-01
TW202120541A (zh) 2021-06-01
US11078261B2 (en) 2021-08-03
KR102352670B1 (ko) 2022-01-19
PE20200011A1 (es) 2020-01-06
CN110582511A (zh) 2019-12-17
AU2021203927A1 (en) 2021-07-08
TWI789644B (zh) 2023-01-11
AU2018255221A1 (en) 2019-09-19
AU2021203927B2 (en) 2024-03-21
KR20220011800A (ko) 2022-01-28
MX2019012445A (es) 2020-01-13
ECSP19075146A (es) 2019-10-31
MA50144A (fr) 2020-07-29
KR20190129100A (ko) 2019-11-19
JP6900500B2 (ja) 2021-07-07

Similar Documents

Publication Publication Date Title
PH12019502361A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
MX355268B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
IL285782A (en) Compounds, compositions, and methods for treating disease
PH12017500032A1 (en) Improved a� protofibril binding antibodies
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
HK1244462A1 (zh) 作為用於癌症治療和診斷之靶標的磷酸甘油酸激酶1的蛋白激酶活性
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
BR112018013256A2 (pt) anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo
BR112017021413A2 (pt) anticorpos anti-flt-1 no tratamento da displasia broncopulmonar.
EP3820477A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
BR112017021416A2 (pt) anticorpos anti-flt-1 no tratamento de displasia broncopulmonar.
SG11201703624PA (en) Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers
GB201911728D0 (en) Bacterial composistions for the treatment of disease
GB201814346D0 (en) Diagnosis of disease
GB201616502D0 (en) The use of brain waves as biomarkers for alzheimers disease and combined treatment for early stage diagnosed patients
TN2013000045A1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
TH1501007171A (th) แอนติ-vegf แอนติบอดีและองค์ประกอบทางเภสัชกรรมสำหรับป้องกัน วินิจฉัย หรือรักษามะเร็ง หรือโรคที่เกี่ยวข้องกับการสร้างหลอดเลือดที่ประกอบด้วยสิ่งเดียวกัน
UA96859U (uk) Застосування рослинного збору "дента-фіт" для лікування запальних захворювань пародонта